article thumbnail

Next week: Accelerate development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity.

article thumbnail

Exclusive event: Accelerate the development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Benefits of higher throughput bioanalytical methods in advanced therapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity.

article thumbnail

How to accelerate the development of advanced biotherapeutics

Drug Discovery World

It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns.